These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 11925101

  • 1. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ, Maihle NJ.
    Exp Cell Res; 2002 Apr 15; 275(1):9-16. PubMed ID: 11925101
    [Abstract] [Full Text] [Related]

  • 2. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
    Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ.
    Oncogene; 2003 Oct 02; 22(43):6679-89. PubMed ID: 14555981
    [Abstract] [Full Text] [Related]

  • 3. Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation.
    Danielsen AJ, Christensen TA, Lovejoy CA, Adelsman MA, Connolly DC, Maihle NJ.
    Exp Cell Res; 2004 Jun 10; 296(2):285-93. PubMed ID: 15149858
    [Abstract] [Full Text] [Related]

  • 4. The erbB gene and the EGF receptor.
    Martin GS.
    Cancer Surv; 1986 Jun 10; 5(2):199-219. PubMed ID: 2877733
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS.
    Gene; 2006 Jan 17; 366(1):2-16. PubMed ID: 16377102
    [Abstract] [Full Text] [Related]

  • 6. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor.
    Ewald JA, Coker KJ, Price JO, Staros JV, Guyer CA.
    Exp Cell Res; 2001 Aug 15; 268(2):262-73. PubMed ID: 11478852
    [Abstract] [Full Text] [Related]

  • 7. Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors.
    Haley JD, Hsuan JJ, Waterfield MD.
    Oncogene; 1989 Mar 15; 4(3):273-83. PubMed ID: 2784850
    [Abstract] [Full Text] [Related]

  • 8. Cell transformation by the epidermal growth factor receptor and v-erbB.
    Hayman MJ, Enrietto PJ.
    Cancer Cells; 1991 Aug 15; 3(8):302-7. PubMed ID: 1681843
    [Abstract] [Full Text] [Related]

  • 9. Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis.
    von Lindern M, Deiner EM, Dolznig H, Parren-Van Amelsvoort M, Hayman MJ, Mullner EW, Beug H.
    Oncogene; 2001 Jun 21; 20(28):3651-64. PubMed ID: 11439328
    [Abstract] [Full Text] [Related]

  • 10. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.
    Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP.
    New Biol; 1990 Nov 21; 2(11):992-1003. PubMed ID: 1983208
    [Abstract] [Full Text] [Related]

  • 11. EGF promotes in vivo tumorigenic growth of primary chicken embryo fibroblasts expressing v-myc and enhances in vitro transformation by the v-erbA oncogene.
    Khazaie K, Panayotou G, Aguzzi A, Samarut J, Gazzolo L, Jurdic P.
    Oncogene; 1991 Jan 21; 6(1):21-8. PubMed ID: 1671532
    [Abstract] [Full Text] [Related]

  • 12. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.
    McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M.
    Oncogene; 2004 Oct 14; 23(47):7810-20. PubMed ID: 15361836
    [Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, Gerald WL, Pincus MR, Osman I, Lee P.
    Oncogene; 2008 May 15; 27(22):3201-10. PubMed ID: 18193092
    [Abstract] [Full Text] [Related]

  • 14. An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex.
    McManus MJ, Boerner JL, Danielsen AJ, Wang Z, Matsumura F, Maihle NJ.
    J Biol Chem; 2000 Nov 10; 275(45):35328-34. PubMed ID: 10954714
    [Abstract] [Full Text] [Related]

  • 15. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X.
    Oncogene; 1998 Jun 04; 16(22):2835-42. PubMed ID: 9671404
    [Abstract] [Full Text] [Related]

  • 16. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
    Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M, Gotoh N, Tsuchida N.
    Oncogene; 2006 Oct 19; 25(49):6457-66. PubMed ID: 16702953
    [Abstract] [Full Text] [Related]

  • 17. Transcriptional regulation of signal regulatory protein alpha1 inhibitory receptors by epidermal growth factor receptor signaling.
    Kapoor GS, Kapitonov D, O'Rourke DM.
    Cancer Res; 2004 Sep 15; 64(18):6444-52. PubMed ID: 15374953
    [Abstract] [Full Text] [Related]

  • 18. Mutational analysis of the role of the carboxy-terminal region of the v-erbB protein in erythroid cell transformation.
    Lee EB, Beug H, Hayman MJ.
    Oncogene; 1993 May 15; 8(5):1317-27. PubMed ID: 8097581
    [Abstract] [Full Text] [Related]

  • 19. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
    Bosch E, Cherwinski H, Peterson D, McMahon M.
    Oncogene; 1997 Aug 28; 15(9):1021-33. PubMed ID: 9285556
    [Abstract] [Full Text] [Related]

  • 20. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
    Basso J, Briggs J, Findlay C, Bos T.
    Oncogene; 2000 Oct 05; 19(42):4876-85. PubMed ID: 11039905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.